BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27073652)

  • 21. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delaying surgery after neoadjuvant chemoradiotherapy in rectal cancer has no influence in surgical approach or short-term clinical outcomes.
    Figueiredo N; Panteleimonitis S; Popeskou S; Cunha JF; Qureshi T; Beets GL; Heald RJ; Parvaiz A
    Eur J Surg Oncol; 2018 Apr; 44(4):484-489. PubMed ID: 29398323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 25. [Idea of Treatment Method for Upper and Lower Rectal Cancer Avoiding Irradiation to Internal and External Sphincter].
    Hatano S; Muta Y; Ito T; Chikatani K; Amano K; Ishiguro T; Kumagai Y; Ishibashi K; Yamano T; Nishimura K; Takahashi T; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2021 Feb; 48(2):239-241. PubMed ID: 33597368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
    Gómez Del Pulgar T; Cebrián A; Fernández-Aceñero MJ; Borrero-Palacios A; Del Puerto-Nevado L; Martínez-Useros J; Marín-Arango JP; Caramés C; Vega-Bravo R; Rodríguez-Remírez M; Cruz-Ramos M; Manzarbeitia F; García-Foncillas J
    J Cell Mol Med; 2016 Sep; 20(9):1729-36. PubMed ID: 27171907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of preoperative chemoradiotherapy with S-1 for advanced rectal cancer: a phase II study.
    Ushigome M; Funahashi K; Kaneko T; Kagami S; Yoshida K; Miura Y; Koda T; Nagashima Y; Kurihara A; Terahara A
    Rep Pract Oncol Radiother; 2023; 28(1):36-46. PubMed ID: 37122915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy].
    Sun Y; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Ye D; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Apr; 19(4):436-41. PubMed ID: 27112480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
    Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term outcomes of a prospective multicenter phase II trial of total neoadjuvant therapy for locally advanced rectal cancer in Japan (ENSEMBLE-1).
    Kagawa Y; Watanabe J; Uemura M; Ando K; Inoue A; Oba K; Takemasa I; Oki E
    Ann Gastroenterol Surg; 2023 Nov; 7(6):968-976. PubMed ID: 37927927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.
    Fokas E; Allgäuer M; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Schmiegel W; Jacobasch L; Weitz J; Folprecht G; Schlenska-Lange A; Flentje M; Germer CT; Grützmann R; Schwarzbach M; Paolucci V; Bechstein WO; Friede T; Ghadimi M; Hofheinz RD; Rödel C;
    J Clin Oncol; 2019 Dec; 37(34):3212-3222. PubMed ID: 31150315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01).
    Yeo SG; Oh JH; Kim DY; Baek JY; Kim SY; Park JW; Kim MJ; Chang HJ; Kim TH; Lee JH; Jang HS; Kim JG; Lee MA; Nam TK
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):34-9. PubMed ID: 23265569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
    Park JH; Yoon SM; Yu CS; Kim JH; Kim TW; Kim JC
    Cancer; 2011 Aug; 117(16):3703-12. PubMed ID: 21328328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T
    Serra-Aracil X; Pericay C; Golda T; Mora L; Targarona E; Delgado S; Reina A; Vallribera F; Enriquez-Navascues JM; Serra-Pla S; Garcia-Pacheco JC;
    Int J Colorectal Dis; 2018 Feb; 33(2):241-249. PubMed ID: 29234923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02.
    Lee JH; Jang HS; Kim JG; Lee MA; Kim DY; Kim TH; Oh JH; Park SC; Kim SY; Baek JY; Park HC; Kim HC; Nam TK; Chie EK; Jung JH; Oh ST
    Radiother Oncol; 2014 Oct; 113(1):18-23. PubMed ID: 25245559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
    Larsen FO; Markussen A; Jensen BV; Fromm AL; Vistisen KK; Parner VK; Linnemann D; Hansen RH; Johannesen HH; Schou JV
    Clin Colorectal Cancer; 2017 Jun; 16(2):e7-e14. PubMed ID: 27743742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.
    Nakagawa R; Inoue Y; Ohki T; Kaneko Y; Maeda F; Yamamoto M
    World J Surg Oncol; 2017 May; 15(1):112. PubMed ID: 28566093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different Impacts of Preoperative Radiotherapy and Chemoradiotherapy on Oncological Outcomes in Patients with Stages II and III Lower Rectal Cancer: A Propensity Score Analysis.
    Takiyama H; Kawai K; Ishihara S; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Nozawa H; Morikawa T; Watanabe T
    Dig Surg; 2018; 35(3):212-219. PubMed ID: 28637039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.